Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents
November 20 2023 - 3:05PM
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing
and precision medicine, today announced it has delivered results to
one million consumers with its SneakPeek® Early Gender DNA
Test. Since 2015, SneakPeek has been providing expectant families
with an easy and convenient way to learn the sex of their baby as
early as six weeks into pregnancy.
SneakPeek is 99% accurate1 and is one of the
earliest ways to learn the baby’s predicted fetal sex. Customers
can choose to take the test at home or have their blood collected
at a local clinic. The at-home test kit includes the innovative
SneakPeek Snap® device, which is placed on the user’s upper
arm and a button is pressed to collect the blood
sample. Samples are mailed to the SneakPeek laboratory and
test results are shared as early as the same day the sample is
received through email.
“When my wife and I were expecting our first baby, we were
curious to learn whether we were having a boy or a girl. As a
bioengineer who had helped develop other prenatal tests, it got me
thinking that there had to be a way to make fetal sex prediction
simple, affordable and more accessible so people could do the test
in the comfort of their own home,” said Chris Jacob, senior vice
president and general manager, Myriad Genetics. “From there,
SneakPeek was born and since then we have served one million
expectant parents, allowing them to easily experience that magical
moment of learning the sex of their baby for the first time.”
In 2022, Myriad acquired Gateway Genomics, a personal genomics
company and the developer of SneakPeek. With the addition of
SneakPeek to the Myriad Genetics portfolio, the company offers a
comprehensive suite of reproductive health testing solutions
before, during and after pregnancy, which also includes the
Prequel® Noninvasive Prenatal Screen, Foresight® Carrier
Screen and MyRisk® Hereditary Cancer Test with RiskScore®.
“This momentous occasion represents an exciting step forward in
expanding access to fetal sex testing at six weeks,” said Melissa
Gonzales, president of women’s health, Myriad Genetics. “Earlier
this year, we also celebrated one million patients being screened
with Prequel. The combined synergies from our products are
providing more patients with relevant information in a way that is
equitable, affordable and easy to use.”
1 See www.sneakpeektest.com/publications for supporting
scientific studies
About Myriad GeneticsMyriad Genetics is a
leading genetic testing and precision medicine company dedicated to
advancing health and well-being for all. Myriad develops and offers
genetic tests that help assess the risk of developing disease or
disease progression and guide treatment decisions across medical
specialties where genetic insights can significantly improve
patient care and lower healthcare costs. For more information,
visit www.myriad.com.
Safe Harbor StatementThis press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements relating to expanding access to fetal sex testing. These
“forward-looking statements” are management’s expectations of
future events as of the date hereof and are subject to known and
unknown risks and uncertainties that could cause actual results,
conditions, and events to differ materially and adversely from
those anticipated. Such factors include those risks described in
the company’s filings with the U.S. Securities and Exchange
Commission, including the company’s Annual Report on Form 10-K
filed on February 25, 2022, as well as any updates to those risk
factors filed from time to time in the company’s Quarterly Reports
on Form 10-Q or Current Reports on Form 8-K. Myriad is not under
any obligation, and it expressly disclaims any obligation, to
update or alter any forward-looking statements, whether as a result
of new information, future events or otherwise except as required
by law.
Media
Contact: |
Investor Contact: |
Glenn Farrell |
Matt Scalo |
(801) 584-1153 |
(801) 584-3532 |
PR@myriad.com |
IR@myriad.com |
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From May 2024 to Jun 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Jun 2023 to Jun 2024